Add-on Effects of Valsartan on Morbi- Mortality (KYOTO HEART Study)


Phase 4 Results

Eligibility Criteria

Inclusion Criteria

- Clinical diagnosis of hypertension
- Clinical diagnosis of one or more risk factors, such as diabetes, smoking habit, lipid metabolism abnormality, history of ischemic heart disease (IHD) or cerebrovascular disease, obesity (BMI>25), chronic heart failure (NYHA II-III), and electrocardiogram (ECG) abnormality (LVH)

Exclusion Criteria

- Patients who have already been administered ARB
- Patients with IHD within 6 months after percutaneous coronary intervention(PCI), and who are stable but are going to implement PCI or coronary artery bypass grafting(CABG)
- Severe/malignant/secondary hypertensive patients
- Pregnant women and women of childbearing potential
- History of heart failure, unstable angina, myocardial infarction, PTCA, or CABG within the preceding 6 months
- Arrhythmia needed to be treated or accompanied with symptoms, second or third degree AV block
- Severe renal impairment (Serum creatinine >3.0 mg/dl)
- Severe hepatic impairment (Hepatic failure, Cirrhosis, etc.)